Animal models with osteoporosi

Bazedoxifene s primary indication is the treatment and prevention of postmenopausal osteoporosis (Miller et al. 2002). In animal models bazedoxifene displays estrogenhke agonistic activity on bone loss and significantly reduces total cholesterol levels with doses as low as 0.1 mg/kg (Miller et al. 2002). Also in these models, there is no evidence of an estrogenic stimulatory effect on the endometrial epithelial cell (Miller et al. 2001). 

Despite the concordance of positive results in vitro, in animal models, and sometimes in clinical studies, estrogenic Isofl are not considered to exert a clear preventative effect on human osteoporosis. As mentioned earlier, the reduction of the excretion of BTM or maintenance of BMD does not strictly indicate a reduction of the risk of bone fracture. In France and in Europe, the food and health agencies have not so far allowed a health claim on osteoporosis prevention. A claim on the prevention of bone loss with daily doses over 60 mg, preferably in two intakes per day, may be more easily obtained. However, as mentioned earlier, such a preventive effect can be achieved only with high doses of Isofl, which are... 

In preclinical models of postmenopausal osteoporosis, lasofoxifene inhibited bone turnover and prevented bone loss throughout the skeleton (Maeda et al. 2004). The primary indication of lasofoxifene is the treatment and prevention of postmenopausal osteoporosis. In preclinical models, lasofoxifene inhibited breast tumor formation and reduced serum cholesterol (Maeda et al. 2004). Lasofoxifene-treated animals did not differ from ovariectomized controls with respect to endometrial thickness and superficial and basal endometrial gladular epithelial luminal area (Maeda et al. 2004 Ke et al. 2004). 

---